Clinical features and survival outcomes of invasive lobular breast carcinoma

Öz

Aim: In this study, we investigated the clinical features and survival outcomes of patients diagnosed with invasive lobular breast cancer who presented to our clinic. Material and Methods: Patients diagnosed with invasive lobular carcinoma who applied to Cumhuriyet University Oncology Center between 2007 and 2019 were examined retrospectively. Results: In the study, the files of 1166 female patients with invasive breast cancer were reviewed, and it was determined that 64 of them (5.5%) had the invasive lobular carcinoma subtype. At diagnosis, 30 patients (47%) were in stage I-II, 31 patients (48%) were in stage III, and 3 patients (5%) were in stage IV. According to histopathological evaluations, 60 patients (94%) were found to be estrogen receptor (ER) positive, 53 patients (83%) were progesterone receptor (PR) positive, and 6 patients (9%) were HER2-positive. Regarding the treatments administered, 48 patients (75%) underwent modified radical mastectomy, 15 patients (23%) underwent breast-conserving surgery, 54 patients (84%) received adjuvant chemotherapy, 55 patients (86%) received hormone therapy, and 44 patients (69%) received radiotherapy. During follow-up, metastasis was detected in 14 patients (22%), with a median time to metastasis of 38 months (range 6-76 months). The 5-year overall survival and disease-free survival were 80% and 73%, respectively. Conclusion: In our study, invasive lobular breast carcinoma was determined to be a common subtype of breast cancer, the majority of which are postmenopausal women, are diagnosed at advanced stages, and histopathologically hormone receptor positivity is common.

Anahtar Kelimeler

• breast cancer
• invasive lobular carcinoma
• clinical features
• survival

İnvaziv lobüler meme karsinomunun klinik özellikleri ve sağkalim sonuçları

Öz

Amaç: Bu çalışmada kliniğimize başvuran invaziv lobuler meme kanseri tanılı hastaların klinik özellikleri ve sağkalım sonuçlarını araştırdık. Gereç ve Yöntemler: Cumhuriyet Üniversitesi Onkoloji Merkezi'ne 2007-2019 yılları arasında başvuranlardan invazif lobüler karsinom tanısı alan hastalar retrospektif olarak incelendi.. Bulgular: Çalışmada 1166 invaziv meme kanseri kadın hastanın dosyası incelenmiş ve bunlardan 64’ünün (5,5%) invaziv lobular meme kanseri alt tipinde olduğu tesbit edilmiştir. Tanıda 30 (47%) hastanın evre I-II, 31 (48%) hastanın evre III ve 3 (5%) hastanın ise evre IV olduğu tesbit edilmiştir. Histopatolojik değerlendirmelere göre hastaların 60’nda (94%) estrogen reseptörü (ER) pozitif, 53’ünde (83%) progesterone reseptörü (PR) pozitif, 6’sında (9%) HER2-pozitif olarak tesbit edildi. Yapılan tedaviler değerlendirildiğinde 48 (75%) hastaya modifiye radikal mastektomi, 15 (23%) hastaya meme koruyucu cerrahi uygulanmıştır ve 54 (84%) hastaya adjuvant kemoterapi, 55 (86%) hastaya hormonterapi ve 44 (69%) hastaya radyoterapi verilmiştir. Takipte 14 (22%) hastada metastaz tesbit edilmiş olup metastaza kadar geçen süre medyan 38 (6-76) aydı. Hastaların 5 yıllık genel sağkalım ve event-free survival sırasıyla 80% ve 73%’tü. Sonuçlar: Çalışmamızda invaziv lobuler karsinomlu hastalar çoğunluğunu postmenopozal kadınların oluşturduğu, daha çok ileri evrelerde tanı alan, histopatolojik olarak hormon reseptörü pozitifliği yaygın görülen meme kanseri alt tipini temsil etmektedir.

Anahtar Kelimeler

• meme kanseri
• invaziv lobuler karsinom
• klinik özellikler
• sağkalım

Kaynakça

1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000 17;406(6797):747-52. https://doi.org/10.1038/35021093.
2. Thomas M, Kelly ED, Abraham J, Kruse M. Invasive lobular breast cancer: a review of pathogenesis, diagnosis, management, and future directions of early stage disease. Semin Oncol. 2019;46(2):121-132. https://doi.org/10.1053/j.seminoncol.2019.03.002.
3. Oesterreich S, Nasrazadani A, Zou J, et al. Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer. J Natl Cancer Inst. 2022;114(11):1511-1522. https://doi.org/10.1093/jnci/djac157.
4. García-Fernández A, Lain JM, Chabrera C, et al. Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival. Breast J. 21(5):533-7. doi: 10.1111/tbj.12455. Epub 2015 Jul 17.
5. Silverstein MJ, Lewinsky BS, Waisman JR, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer. 1994 15;73(6):1673-7. https://doi.org/10.1002/1097-0142(19940315)73:6<1673::aid-cncr2820730620>3.0.co;2-b.
6. Raap M, Antonopoulos W, Dammrich M, et al. High frequency of lobular breast cancer in distant metastases to the orbit. Cancer Med. 2015 Jan;4(1):104-11. https://doi.org/10.1002/cam4.331.
7. Mathew A, Rajagopal PS, Villgran V, et al. Distinct pattern of metastases in patients with invasive lobular carcinoma of the breast. Geburtshilfe Frauenheilkd. 2017;77(6):660-666. doi:10.1055/s-0043-109374.
8. Fortunato L, Mascaro A, Poccia I, et al. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period. Ann Surg Oncol. 2012 Apr;19(4):1107-14. doi: 10.1245/s10434-011-1907-9. Epub 2011 Sep 13.

9. Adachi Y, Ishiguro J, Kotani H, et al. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer. 2016;16:248. doi:10.1186/s12885-016-2275-4.
10. Pestalozzi BC, Zahrieh D, Mallon E, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008; 26(18):3006-3014. doi:10.1200/J Clin Oncol.2007.14.9336.
11. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan 1;25(1):118-45. doi: 10.1200/JCO.2006.09.2775.
12. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529.
13. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-47. doi: 10.1093/annonc/mdr304.
14. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002;11(7):601-7.
15. Findlay-Shirras LJ, Lima I, Smith G, Clemons M, Arnaout A. Population Trends in Lobular Carcinoma of the Breast: The Ontario Experience. Ann Surg Oncol. 2020;27(12):4711-4719. doi: 10.1245/s10434-020-08895-8.
16. Kee GJ, Tan RY, Rehena S, et al. Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience. World J Clin Oncol. 2020:24;11(5):283-293. doi: 10.5306/wjco.v11.i5.283.
17. Chamalidou C, Fohlin H, Albertsson P, et a. Swedish western and south-eastern breast cancer groups. Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up. Breast. 2021;59:294-300. doi: 10.1016/j.breast.2021.07.011. Epub 2021 Jul 22.